FDA Makes Big Moves Amid Spread of Omicron Variant

With a rising number of COVID-19 cases due to the omicron variant, the FDA is making big moves. First, Pfizer's COVID-19 booster has been authorized for those ages 12 to 15. The agency also reduced the amount of time to wait between receiving a second vaccine dose and booster from six months to five. Finally, a third primary series dose of Pfizer's shot is approved for immunocompromised children five to 11 years old. Professor Peter Pitts joins Cheddar News to discuss.